Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 46.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Precision BioSciences was 47.40% per year. The lowest was -46.50% per year. And the median was 30.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Precision BioSciences 5-Year EBITDA Growth Rate Related Terms
DTIL vs NERV, VYGR, GLSI: 5-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Precision BioSciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precision BioSciences 5-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precision BioSciences's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Precision BioSciences's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Precision BioSciences (DTIL) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Precision BioSciences and its competitors.
Is Precision BioSciences' 5-Year EBITDA Growth Rate too high?
Precision BioSciences' current 5-Year EBITDA Growth Rate is 0.00%. Overall, Precision BioSciences has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' 5-Year EBITDA Growth Rate compare to NERV and VYGR?
Precision BioSciences' 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Precision BioSciences and its competitors. Precision BioSciences's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (DTIL) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.89, compared to a current price of $7.52 — trading 297.9% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Precision BioSciences' overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Precision BioSciences (DTIL), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precision BioSciences (DTIL) Overvalued in 2026?
Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued.
The current stock price of $7.52 is trading 297.9% above its estimated GF Value™ of $1.89.
GuruFocus considers Precision BioSciences to be Significantly Overvalued.
Key valuation signals for DTIL:
5-Year EBITDA Growth Rate: 0.00%
GF Value™: $1.89 vs. price of $7.52 (297.9% above fair value)
No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
45GF Score
Get the complete analysis for DTIL
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DTIL has been successfully added to your 
